An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs GSK 239512 (Primary) ; Ketoconazole (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Acronyms DDI Study
- Sponsors GSK
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2013 New trial record